Jean P. Cornet

Array ( [id] => 20407327 [patent_doc_number] => 20250376436 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => Selective Serotonin Receptor Modulators and Methods of Making and Using the Same [patent_app_type] => utility [patent_app_number] => 19/311344 [patent_app_country] => US [patent_app_date] => 2025-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45516 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19311344 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20335303 [patent_doc_number] => 20250339423 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-06 [patent_title] => METHODS FOR TREATING NEUTROPENIA [patent_app_type] => utility [patent_app_number] => 19/269675 [patent_app_country] => US [patent_app_date] => 2025-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19269675 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20287094 [patent_doc_number] => 20250312337 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-09 [patent_title] => STABLE LIQUID COMPOSITIONS OF NETUPITANT AND PALONOSETRON [patent_app_type] => utility [patent_app_number] => 19/244626 [patent_app_country] => US [patent_app_date] => 2025-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 126 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19244626 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20287083 [patent_doc_number] => 20250312326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-09 [patent_title] => PHARMACEUTICAL COMPOSITION OF ANTIPLATELET DRUG, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/243756 [patent_app_country] => US [patent_app_date] => 2025-06-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17316 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19243756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023053 [patent_doc_number] => 20250161275 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS [patent_app_type] => utility [patent_app_number] => 19/029592 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41053 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19029592 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20023052 [patent_doc_number] => 20250161274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-22 [patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS [patent_app_type] => utility [patent_app_number] => 19/029360 [patent_app_country] => US [patent_app_date] => 2025-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -51 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19029360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19982711 [patent_doc_number] => 20250120933 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-17 [patent_title] => AGENT FOR INHIBITING RENAL DAMAGE INDUCED BY RHABDOMYOLYSIS [patent_app_type] => utility [patent_app_number] => 19/001859 [patent_app_country] => US [patent_app_date] => 2024-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19001859 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20127890 [patent_doc_number] => 12370190 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Stable liquid compositions of netupitant and palonosetron [patent_app_type] => utility [patent_app_number] => 18/794778 [patent_app_country] => US [patent_app_date] => 2024-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8605 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18794778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402109 [patent_doc_number] => 20240285620 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF COUGH [patent_app_type] => utility [patent_app_number] => 18/640100 [patent_app_country] => US [patent_app_date] => 2024-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19402070 [patent_doc_number] => 20240285581 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => METHODS OF TREATING ACUTE CORONARY SYNDROME USING 3,3'-DIINDOLYLMETHANE [patent_app_type] => utility [patent_app_number] => 18/629099 [patent_app_country] => US [patent_app_date] => 2024-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28122 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18629099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379264 [patent_doc_number] => 20240269134 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF) [patent_app_type] => utility [patent_app_number] => 18/621976 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26479 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19584905 [patent_doc_number] => 20240382462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => PRESBYOPIA TREATMENTS [patent_app_type] => utility [patent_app_number] => 18/621624 [patent_app_country] => US [patent_app_date] => 2024-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14405 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18621624 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599423 [patent_doc_number] => 20240390303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => CHEMICALLY MODIFIED CURCUMINS FOR USE IN THE PRODUCTION OF LIPOXINS [patent_app_type] => utility [patent_app_number] => 18/612665 [patent_app_country] => US [patent_app_date] => 2024-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18612665 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19267035 [patent_doc_number] => 20240210736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => MOUSE MYOPIA-INDUCED MODEL AND ENDOPLASMIC RETICULUM STRESS SUPPRESSANT FOR PREVENTING AND SUPPRESSING MYOPIA [patent_app_type] => utility [patent_app_number] => 18/600985 [patent_app_country] => US [patent_app_date] => 2024-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18600985 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462349 [patent_doc_number] => 20240316018 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => CAPSID INHIBITORS FOR THE TREATMENT OF HIV [patent_app_type] => utility [patent_app_number] => 18/588730 [patent_app_country] => US [patent_app_date] => 2024-02-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18588730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19622864 [patent_doc_number] => 12161656 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Tetracycline compositions [patent_app_type] => utility [patent_app_number] => 18/583643 [patent_app_country] => US [patent_app_date] => 2024-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 17882 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18583643 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19232031 [patent_doc_number] => 20240189222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => READY-TO-USE INJECTABLE PHARMACEUTICAL COMPOSITIONS COMPRISING NEOSTIGMINE AND GLYCOPYRROLATE [patent_app_type] => utility [patent_app_number] => 18/444310 [patent_app_country] => US [patent_app_date] => 2024-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18444310 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19762152 [patent_doc_number] => 12220422 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-11 [patent_title] => Compositions and methods for treating epilepsy [patent_app_type] => utility [patent_app_number] => 18/442061 [patent_app_country] => US [patent_app_date] => 2024-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 21 [patent_no_of_words] => 51950 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18442061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19875790 [patent_doc_number] => 20250108047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => ARIPIPRAZOLE FORMULATIONS HAVING INCREASED INJECTION SPEEDS [patent_app_type] => utility [patent_app_number] => 18/440388 [patent_app_country] => US [patent_app_date] => 2024-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18440388 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316770 [patent_doc_number] => 20240238310 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => MODULATION OF SEX STEROID HORMONE PRODUCTION AND ACTIVITY FOR TREATING AND PREVENTING HERNIAS [patent_app_type] => utility [patent_app_number] => 18/434367 [patent_app_country] => US [patent_app_date] => 2024-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20072 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18434367 [rel_patent_id] =>[rel_patent_doc_number] =>)